Immunic, Inc. (IMUX)
7.79
-0.33
(-4.06%)
USD |
NASDAQ |
Nov 12, 16:00
7.71
-0.08
(-1.03%)
Pre-Market: 08:00
Immunic Enterprise Value : -48.24M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | -48.24M |
| November 11, 2026 | -43.74M |
| November 10, 2026 | -44.83M |
| November 09, 2026 | -45.92M |
| November 06, 2026 | -48.79M |
| November 05, 2026 | -54.65M |
| November 04, 2026 | -46.19M |
| November 03, 2026 | -50.83M |
| November 02, 2026 | -54.38M |
| October 30, 2026 | -52.06M |
| October 29, 2026 | -48.17M |
| October 28, 2026 | -45.65M |
| October 27, 2026 | -50.70M |
| October 26, 2026 | -55.20M |
| October 23, 2026 | -53.43M |
| October 22, 2026 | -56.02M |
| October 21, 2026 | -52.47M |
| October 20, 2026 | -53.43M |
| October 19, 2026 | -59.16M |
| October 16, 2026 | -59.43M |
| October 15, 2026 | -57.66M |
| October 14, 2026 | -63.66M |
| October 13, 2026 | -60.52M |
| October 12, 2026 | -46.06M |
| October 09, 2026 | -42.78M |
| Date | Value |
|---|---|
| October 08, 2026 | -51.38M |
| October 07, 2026 | -50.42M |
| October 06, 2026 | -47.83M |
| October 05, 2026 | -44.42M |
| October 02, 2026 | -45.92M |
| October 01, 2026 | -36.64M |
| September 30, 2026 | -27.64M |
| September 29, 2026 | -32.96M |
| September 28, 2026 | -24.77M |
| September 25, 2026 | -27.02M |
| September 24, 2026 | -27.36M |
| September 23, 2026 | -26.68M |
| September 22, 2026 | -6.625M |
| September 21, 2026 | -6.761M |
| September 18, 2026 | -9.626M |
| September 17, 2026 | -13.31M |
| September 16, 2026 | -16.45M |
| September 15, 2026 | -13.04M |
| September 14, 2026 | -1.303M |
| September 11, 2026 | 1.289M |
| September 10, 2026 | 7.020M |
| September 09, 2026 | 11.80M |
| September 08, 2026 | 19.30M |
| September 04, 2026 | 24.35M |
| September 03, 2026 | 19.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.230B |
| Sionna Therapeutics, Inc. | -61.75M |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 166.16M |
| Savara, Inc. | 870.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.10M |
| Total Expenses (Quarterly) | 34.10M |
| EPS Diluted (Quarterly) | -0.8021 |
| Earnings Yield | -61.69% |
| Normalized Earnings Yield | -61.69 |